Key Drivers
- Cash-rich balance sheet
- No revenue
- Ongoing cash burn
AIAI Summary
RLMD has shifted from a pure speculative biotech to a better-capitalized, near-term catalyst story with cash runway through 2029 and a Phase 3 start targeted for mid-2026, but the investment case still hinges almost entirely on NDV-01 execution and any clinical setback would likely reprice the stock quickly because there is no revenue cushion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash-rich balance sheet
- •No revenue
- •Ongoing cash burn
RLMD has a fortress-like cash position and minimal liabilities, but with no revenue, persistent operating losses, and ongoing cash burn, its value remains balance-sheet driven rather than earnings-driven.
Price Behavior
Key Price Behavior Insights:
- •Rebound faded
- •Support holding
- •Resistance overhead
RLMD was broadly flat over the last month, rebounded sharply from $5.72 to $6.98, but then faded back to $6.28 near $6.25-$6.30 support, leaving momentum weak and $6.90-$7.00 as resistance.
Sharp rebound from $5.72 to $6.98 before slipping back to $6.28
Sentiment & News
Key News Insights:
- •CNS Support
- •Analyst Coverage
- •Index Inclusion
Relmada advanced both its CNS and oncology pipelines in June while boosting investor visibility through analyst coverage and Russell index inclusion.
The updates may improve investor attention and credibility, but sustained upside will depend on clinical progress and execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings